Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic review and meta-analysis

Table 1 Main characteristic of included studies

Ref.	Country	Design	Sample size	Male %	Severity of COVID-19	Bamlanivimab			Comparison(s)
						n	Mean age	Comorbidity1	Name	n	Mean age	Comorbidity1
Alam et al[19], 2021	United States	RS	264	44	MM	160	81	58.1	SOC	86	84	51.2
Bariola et al[13], 2021	United States	RS	1392	44.39	MM	232	67.3	75.9	SOC	1160	67.1	73.6
Brock et al[20], 2021	United States	RS	108	NA	MM	58	NA	100	SOC	58	NA	100
Chen et al[21], 2021	United States	RCT	24	54	MC	18	NA	NA	PBO	6	43.2	NA
Chen et al[21], 2021	United States	RCT	452	44.9	MM	309	45	69.6	PBO	143	46	66.4
Chew et al[23], 2022	United States	RCT	317	51.1	MS	159	NA	NA	PBO	158	NA	NA
Cooper et al[24], 2021	United States	RS	5758	45.13	NA	1718	60	56.3	SOC, B/E, C/I	4040	NA	> 50
Corwin et al[25], 2021	United States	RS	6117	42.7	MM	780	62.6	68.1	SOC	5337	56.7	47.1
Destache et al[14], 2021	United States	RS	234	47	MM	117	72	69.2	SOC	117	72	63.3
Djuric et al[26], 2022	Serbia	RS	31	67.74	MS	13	62.2	30.8	SOC	18	65.9	38.9
Farcy et al[11], 2022	United States	PS	321	60.12	MM	201	64.2	56.2	C/I	120	66.3	58.3
San Filippo et al[39], 2022	United States	RS	453	47.01	MM	183	66.9	44.8	C/I	270	63.4	51.9
Ganesh et al[27], 2021	United States	RS	4670	50.62	MM	2335	63	54.2	SOC	2335	63	55.1
Ganesh et al[28], 2021	United States	RS	3596	50.02	MM	2747	NA	53.3	C/I	849	NA	48.3
Gottlieb et al[29], 2021	United States	RCT	577	45.40	MM	309	NA	NR	PBO, B/E	156	NA	NA
Heller et al[31], 2023	Germany	RS	26	45	MM	10	81	NR	SOC, C/I	23	NA	NA
Iqbal et al[8], 2021	United States	RS	284	NA	MM	144	NR	10.3	SOC	140	NA	63.60
Karr et al[10], 2022	United States	RS	46	63.04	MM	40	69	65	SOC	6	69	50
Kumar et al[32], 2022	United States	RS	403	52.10	MM	218	66	50.5	SOC	185	62	43.8
ACTIV-3/TICO LY-CoV555 Study Group et al[30], 2021	United States	RCT	314	57.32	NA	163	63	72	PBO	151	59	65
McCreary et al[33], 2021	United States	RCT	1935	46.20	MM	128	57	47	B/E, C/I	1807	NA	NA
Monday et al[34], 2022	United States	RCT	643	42.76	MM	294	61	72.8	B/E	349	55	72.4
Murillo et al[35], 2022	United States	RS	107	42.99	MM	39	NA	NA	SOC	63	NA	NA
Priest et al[36], 2022	United States	RS	758	49	MM	379	NA	88	SOC	379	NA	88
Quenzer et al[37], 2022	United States	RS	270	51.85	MM	134	60.3	92.5	SOC	136	63.3	69.1
Rubin et al[38], 2021	United States	RS	1257	43.75	NA	191	64	NR	SOC	1066	64.6	NA
Savoldi et al[40], 2022	Italy	PS	635	61.57	MM	161	63	72.7	B/E, C/I	474	NR	NA
Sridhara et al[41], 2023	United States	RS	2182	42.98	NA	1099	64	52.8	SOC	1091	46	20.9
Voelker and Jerath[42], 2022	United States	PS	678	43.65	NA	380	NA	NA	C/I	298	NA	NA
Webb et al[43], 2021	United States	QES	13534	55.19	NA	479	65	90.8	SOC, C/I	5651	NA	NA

¹The percentage of patients with at least one comorbidity.

B/E: Bamlanivimab/etesevimab; C/I: Casirivimab/imdevimab; QES: Quasi-experimental study; MM: Mild to moderate; MS: Mild to severe; MC: Mild to critical; mAb: Monoclonal antibody; N: Number; NA: Not acquired; PBO: Placebo; PS: Prospective study; RCT: Randomized clinical trial; RS: Retrospective study; SOC: Standard of care.